SUMMARY
Bradley C. Leibovich, M.D., studies the diagnosis, pathogenesis, treatment and prognostic factors of urological malignancies. The research of Dr. Leibovich includes molecular biology, biomarkers and immunologic factors in disease progression in cell carcinoma. His work also includes artificial intelligence (AI) in urology and healthcare delivery. The use of AI to design digital tools improves healthcare delivery, and disease prediction and prevention. Dr. Leibovich's work on predicting renal cell carcinoma prognosis includes the Leibovich score, an internationally used tool.
Focus areas
- Renal cell carcinoma biomarkers. Dr. Leibovich's work led to the discovery and development of immune-based predictors of prognosis and to U.S. Food and Drug Administration-approved systemic checkpoint blockade treatments.
- Development of algorithms in renal cell carcinoma. Algorithms in renal cell carcinoma are used to predict prognosis and make therapeutic decisions.
- Data acquisition in urological cancer. Dr. Leibovich's data acquisition and analysis approaches improve surgical and nonsurgical care for patients with urological cancers.
- Machine learning approaches to renal tumors. Machine learning approaches to the segmentation of renal tumors using CT scans were developed and are now in clinical use. Dr. Leibovich's ongoing radiomic work aims to develop a radiological biopsy that includes histological features and predictions of disease biology.
- Remote data acquisition. Dr. Leibovich studies remote data acquisition for disease prediction, prevention and interception.
- Digital care delivery. Dr. Leibovich's other areas of research include digital care delivery, platforms, decision support, and AI-enabled data presentation and insights.
Significance to patient care
For most of his career, Dr. Leibovich has focused on renal cancer in both his research and his clinical work. He studies factors that affect how the disease happens and progresses, including its immune and cellular biology. His work finding key genomic and proteomic factors helps improve patient outcomes. By using large datasets and advanced tools, Dr. Leibovich finds new ways to predict, diagnose, treat and prevent disease while expanding access to high-quality care for all.
Professional highlights
- Society of Urologic Oncology:
- Education chair, 2023-present.
- Member, Board of directors, Clinical Trials Consortium, 2019-present.
- Kidney Cancer Association:
- Chair, Board of directors, 2022-present.
- Andrew C. Novick Award, 2014.
- Mayo Clinic:
- David C. Utz, M.D., Professor of Urology, 2015-present.
- Medical director, Center for Digital Health, 2020-2026.
- Team Science Award, 2023.
- Chair, Department of Urology, 2013-2021.